Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Aug 21;157(4):263-75.
doi: 10.7326/0003-4819-157-4-201208210-00007.

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

Suetonia C Palmer  1 , Jonathan C Craig, Sankar D Navaneethan, Marcello Tonelli, Fabio Pellegrini, Giovanni F M Strippoli
Affiliations
Meta-Analysis

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

Suetonia C Palmer et al. Ann Intern Med. .

Abstract

Background: Statins have uncertain benefits in persons with chronic kidney disease (CKD) because individual trials may have insufficient power to determine whether treatment effects differ with severity of CKD.

Purpose: To summarize the benefits and harms of statin therapy for adults with CKD and examine whether effects of statins vary by stage of kidney disease.

Data sources: Cochrane and EMBASE databases (inception to February 2012).

Study selection: Randomized trials comparing the effects of statins with placebo, no treatment, or another statin on mortality and cardiovascular outcomes.

Data extraction: Two independent reviewers extracted data and assessed risk of bias.

Data synthesis: Eighty trials comprising 51099 participants compared statin with placebo or no treatment. Treatment effects varied with stage of CKD. Moderate- to high-quality evidence indicated that statins reduced all-cause mortality (relative risk [RR], 0.81 [95% CI, 0.74 to 0.88]), cardiovascular mortality (RR, 0.78 [CI, 0.68 to 0.89]), and cardiovascular events (RR, 0.76 [CI, 0.73 to 0.80]) in persons not receiving dialysis. Moderate- to high-quality evidence indicated that statins had little or no effect on all-cause mortality (RR, 0.96 [CI, 0.88 to 1.04]), cardiovascular mortality (RR, 0.94 [CI, 0.82 to 1.07]), or cardiovascular events (RR, 0.95 [CI, 0.87 to 1.03]) in persons receiving dialysis. Effects of statins in kidney transplant recipients were uncertain. Statins had little or no effect on cancer, myalgia, liver function, or withdrawal from treatment, although adverse events were evaluated systematically in fewer than half of the trials.

Limitation: There was a reliance on post hoc subgroup data for earlier stages of CKD.

Conclusion: Statins decrease mortality and cardiovascular events in persons with early stages of CKD, have little or no effect in persons receiving dialysis, and have uncertain effects in kidney transplant recipients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Risk of bias in trials comparing statin regimens with placebo or no treatment
Figure 2
Figure 2
Effect of statin therapy versus placebo or no treatment control on total and cardiovascular mortality and major cardiovascular events, grouped by stage of chronic kidney disease. 95% CI, 95% confidence interval; CKD, chronic kidney disease. *Subsets of trials refers to presence of data from subgroups with chronic kidney disease not on dialysis or cohorts on various types of dialysis (peritoneal dialysis or hemodialysis) within broader trials
Figure 3
Figure 3
Summary of adverse effects for statins versus placebo or no treatment control in people with chronic kidney disease (any stage). 95% CI, 95% confidence interval; CKD, chronic kidney disease
See this image and copyright information in PMC

Comment in

References

    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–9. - PubMed
    1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782–9. - PubMed
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. - PubMed
    1. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis. 2007;49(3):373–82. - PubMed
    1. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis. 2010;55(1):42–9. - PMC - PubMed

MeSH terms

Substances